[The use of Enduracin--a prolonged-action form of nicotinic acid--in correcting atherogenic dyslipidemias].
The hypolipidemic effects of induracin, a new long-acting nicotinic acid dosage form based on the waxy matrix, and its tolerance were studied in 31 patients with Types IIa and IIb hyperlipoproteinemias in a 6-month blind crossover study. There were decreases in the levels of total cholesterol by 9-13% and low density lipoprotein cholesterol by 12-22%, an increase in high density lipoprotein cholesterol by 12-15%, and a good dynamics in the ratio of blood lipid-transport proteins--a 12-16% increase to the levels of apoprotein AI to a 29% decrease in those of apoprotein B. The drug is well tolerated by patients and may be recommended for correction of atherogenic dyslipidemias.
Oganov
R G
RG
Kiseleva
N G
NG
Aronov
D M
DM
Akhmedzhanov
N M
NM
Olfer'ev
A M
AM
Kiseleva
N S
NS
Perova
N V
NV
D000328:Adult; D000368:Aged; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy* / Q000209:etiology; D003327:Coronary Disease / Q000097:blood / Q000150:complications / Q000188:drug therapy; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000627:therapeutic use*; D013997:Time Factors
D003692:Delayed-Action Preparations; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D009525:Niacin
Primenenie enduratsina--prolongirovannoĭ formy nikotinovoĭ kisloty--v korrektsii aterogennykh dislipidemiĭ.